{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:50:27Z","timestamp":1780465827131,"version":"3.54.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA099168"],"award-info":[{"award-number":["U01CA099168"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA247643"],"award-info":[{"award-number":["U24CA247643"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA190423"],"award-info":[{"award-number":["R01CA190423"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001857"],"award-info":[{"award-number":["UL1TR001857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00280-022-04430-6","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T12:03:14Z","timestamp":1650283394000},"page":"721-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer"],"prefix":"10.1007","volume":"89","author":[{"given":"Julia","family":"Manzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Puhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalu","family":"Pahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Stoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Diergaarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra P.","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Wahner Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Visscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Oesterreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuping","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph E.","family":"Parchment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Giranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie P.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ETCTN-8282 study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"25","key":"4430_CR1","doi-asserted-by":"publisher","first-page":"23028","DOI":"10.1074\/jbc.M202390200","volume":"277","author":"V Schreiber","year":"2002","unstructured":"Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277(25):23028\u201323036. https:\/\/doi.org\/10.1074\/jbc.M202390200","journal-title":"J Biol Chem"},{"issue":"3","key":"4430_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nsmb.2501","volume":"20","author":"M Berti","year":"2013","unstructured":"Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M, Odreman F, Glatter T, Graziano S, Mendoza-Maldonado R, Marino F, Lucic B, Biasin V, Gstaiger M, Aebersold R, Sidorova JM, Monnat RJ Jr, Lopes M, Vindigni A (2013) Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol 20(3):347\u2013354. https:\/\/doi.org\/10.1038\/nsmb.2501","journal-title":"Nat Struct Mol Biol"},{"issue":"7612","key":"4430_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A (2016) Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535(7612):382\u2013387. https:\/\/doi.org\/10.1038\/nature18325","journal-title":"Nature"},{"issue":"7035","key":"4430_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913\u2013917. https:\/\/doi.org\/10.1038\/nature03443","journal-title":"Nature"},{"issue":"7035","key":"4430_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"issue":"10","key":"4430_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer 4(10):814\u2013819. https:\/\/doi.org\/10.1038\/nrc1457","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"4430_CR7","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Can Res 72(21):5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753","journal-title":"Can Res"},{"issue":"9","key":"4430_CR8","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13(9):2728\u20132737. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3039","journal-title":"Clin Cancer Res"},{"issue":"23","key":"4430_CR9","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2174\/092986712802002464","volume":"19","author":"D Davar","year":"2012","unstructured":"Davar D, Beumer JH, Hamieh L, Tawbi H (2012) Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 19(23):3907\u20133921","journal-title":"Curr Med Chem"},{"issue":"16","key":"4430_CR10","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","volume":"27","author":"S Kummar","year":"2009","unstructured":"Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27(16):2705\u20132711. https:\/\/doi.org\/10.1200\/JCO.2008.19.7681","journal-title":"J Clin Oncol"},{"key":"4430_CR11","doi-asserted-by":"crossref","unstructured":"Puhalla S, Beumer JH, Pahuja S, Appleman LJ, Tawbi HA, Stoller RG, Lee JJ, Lin Y, Kiesel B, Yu J, Tan AR, Belani CP, Chew HK, Garcia AA, Morgan R, Giranda VL, Shepherd SP, Chen AP, Chu E (2014) Final Results of a Phase 1 Study of Chronically-Dosed, Single-Agent Veliparib (ABT-888) in Patients with Either BRCA 1\/2 \u2013Mutated Cancer (BRCA+), Platinum-Refractory Ovarian or Basal-Like Breast Cancer (BRCA-wt). In: Proceedings of the American Society of Clinical Oncology (Supplement to Journal of Clinical Oncology), vol 5S","DOI":"10.1200\/jco.2014.32.15_suppl.2570"},{"issue":"11","key":"4430_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","volume":"94","author":"DM Euhus","year":"2002","unstructured":"Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94(11):844\u2013851","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4430_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45(3):925\u2013937","journal-title":"Biometrics"},{"issue":"3","key":"4430_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1\u20132","key":"4430_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jchromb.2008.07.032","volume":"872","author":"RA Parise","year":"2008","unstructured":"Parise RA, Shawaqfeh M, Egorin MJ, Beumer JH (2008) Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. J Chromatogr, B: Anal Technol Biomed Life Sci 872(1\u20132):141\u2013147. https:\/\/doi.org\/10.1016\/j.jchromb.2008.07.032","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"issue":"22","key":"4430_CR16","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM (2011) Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29(22):3008\u20133015. https:\/\/doi.org\/10.1200\/JCO.2010.34.2980","journal-title":"J Clin Oncol"},{"issue":"6","key":"4430_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00280-019-03960-w","volume":"84","author":"LJ Appleman","year":"2019","unstructured":"Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS (2019) Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 84(6):1289\u20131301. https:\/\/doi.org\/10.1007\/s00280-019-03960-w","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"4430_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/jcph.892","volume":"57","author":"J Niu","year":"2017","unstructured":"Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH (2017) Parent-metabolite pharmacokinetic modeling and pharmacodynamics of veliparib (ABT-888), a PARP inhibitor, in patients with BRCA 1\/2-mutated cancer or PARP-sensitive tumor types. J Clin Pharmacol 57(8):977\u2013987. https:\/\/doi.org\/10.1002\/jcph.892","journal-title":"J Clin Pharmacol"},{"key":"4430_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv437","author":"MA Villalona-Calero","year":"2016","unstructured":"Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C (2016) Veliparib alone or in combination with mitomycin C in patients with solid tumors with functional deficiency in homologous recombination repair. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv437","journal-title":"J Natl Cancer Inst"},{"issue":"7418","key":"4430_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"N Cancer Genome Atlas","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"2","key":"4430_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O\u2019Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM (2019) BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov 9(2):210\u2013219. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0715","journal-title":"Cancer Discov"},{"issue":"6","key":"4430_CR22","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","volume":"287","author":"AG Patel","year":"2012","unstructured":"Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH (2012) Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287(6):4198\u20134210. https:\/\/doi.org\/10.1074\/jbc.M111.296475","journal-title":"J Biol Chem"},{"issue":"1","key":"4430_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","volume":"153","author":"RM Hurley","year":"2019","unstructured":"Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH (2019) 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol 153(1):127\u2013134. https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.015","journal-title":"Gynecol Oncol"},{"issue":"20","key":"4430_CR24","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","volume":"70","author":"N Chan","year":"2010","unstructured":"Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM, Bristow RG (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Can Res 70(20):8045\u20138054. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2352","journal-title":"Can Res"},{"issue":"1","key":"4430_CR25","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1","journal-title":"Lancet Oncol"},{"issue":"22","key":"4430_CR26","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"issue":"10106","key":"4430_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O\u2019Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, investigators A, (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106):1949\u20131961. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6","journal-title":"Lancet"},{"issue":"8","key":"4430_CR28","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","volume":"25","author":"J Balmana","year":"2014","unstructured":"Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE (2014) Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol 25(8):1656\u20131663. https:\/\/doi.org\/10.1093\/annonc\/mdu187","journal-title":"Ann Oncol"},{"issue":"5","key":"4430_CR29","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1186\/bcr3484","volume":"15","author":"RA Dent","year":"2013","unstructured":"Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J (2013) Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 15(5):R88. https:\/\/doi.org\/10.1186\/bcr3484","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4430_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16(1):87\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(14)71135-0","journal-title":"Lancet Oncol"},{"issue":"4","key":"4430_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10637-019-00856-7","volume":"38","author":"R van der Noll","year":"2020","unstructured":"van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM (2020) Phase I study of continuous olaparib capsule dosing in combination with carboplatin and\/or paclitaxel (Part 1). Invest New Drugs 38(4):1117\u20131128. https:\/\/doi.org\/10.1007\/s10637-019-00856-7","journal-title":"Invest New Drugs"},{"issue":"3","key":"4430_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","volume":"148","author":"HJ Gray","year":"2018","unstructured":"Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP (2018) Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol 148(3):507\u2013514. https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.029","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4430_CR33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/1078-0432.CCR-18-2014","volume":"25","author":"F Atrafi","year":"2019","unstructured":"Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A (2019) A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors. Clin Cancer Res 25(2):496\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4430_CR34","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-15-2137","volume":"22","author":"ET Rodler","year":"2016","unstructured":"Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM (2016) Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and\/or BRCA mutation-associated breast cancer. Clin Cancer Res 22(12):2855\u20132864. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2137","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"4430_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2020.38.15_suppl.1001","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Rodler E, Barlow WE, Gralow J, Huggins-Puhalla SL, Anders CK, Goldstein LJ, Brown-Glaberman UA, Huynh T-T, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN (2020) Results of a phase II randomized trial of cisplatin +\/- veliparib in metastatic triple-negative breast cancer (TNBC) and\/or germline BRCA-associated breast cancer (SWOG S1416). JCO 38(15_suppl):1001\u20131001. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1001","journal-title":"JCO"},{"issue":"25","key":"4430_CR36","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381(25):2403\u20132415. https:\/\/doi.org\/10.1056\/NEJMoa1909707","journal-title":"N Engl J Med"},{"issue":"10","key":"4430_CR37","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Dieras","year":"2020","unstructured":"Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palacova M, Park YH, Shparyk Y, Yanez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269\u20131282. https:\/\/doi.org\/10.1016\/S1470-2045(20)30447-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"4430_CR38","doi-asserted-by":"publisher","first-page":"dju089","DOI":"10.1093\/jnci\/dju089","volume":"106","author":"JM Lee","year":"2014","unstructured":"Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC (2014) Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106(6):dju089. https:\/\/doi.org\/10.1093\/jnci\/dju089","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"4430_CR39","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.18632\/oncotarget.26869","volume":"10","author":"EJ Lampert","year":"2019","unstructured":"Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM (2019) Phase I\/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget 10(30):2855\u20132868. https:\/\/doi.org\/10.18632\/oncotarget.26869","journal-title":"Oncotarget"},{"key":"4430_CR40","doi-asserted-by":"crossref","unstructured":"Pahuja S, Beumer JH, Appleman LJ, Tawbi H, Stoller R, Lee JJ, Lin Y, Ding F, Yu J, Belani C, Chen A, Giranda V, Shepherd SP, Chu E, Puhalla S (2015) A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple negative breast cancer (TNBC). In: Annual Meeting American Society of Clinical Oncology, Chicago. Proceedings of the American Society of Clinical Oncology (Supplement to Journal of Clinical Oncology), vol 152623","DOI":"10.1200\/jco.2015.33.15_suppl.1015"},{"issue":"15","key":"4430_CR41","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","volume":"23","author":"G Somlo","year":"2017","unstructured":"Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN (2017) Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: california cancer consortium trial NCT01149083. Clin Cancer Res 23(15):4066\u20134076. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2714","journal-title":"Clin Cancer Res"},{"issue":"19","key":"4430_CR42","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R (2015) FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 21(19):4257\u20134261. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0887","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4430_CR43","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852\u2013861. https:\/\/doi.org\/10.1016\/S1470-2045(11)70214-5","journal-title":"Lancet Oncol"},{"issue":"9","key":"4430_CR44","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882\u2013892. https:\/\/doi.org\/10.1016\/S1470-2045(13)70240-7","journal-title":"Lancet Oncol"},{"key":"4430_CR45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2796","author":"R Kristeleit","year":"2017","unstructured":"Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmana J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R (2017) A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2796","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4430_CR46","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"RL Coleman","year":"2015","unstructured":"Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM (2015) A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation\u2014an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol 137(3):386\u2013391. https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.042","journal-title":"Gynecol Oncol"},{"issue":"9737","key":"4430_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235\u2013244. https:\/\/doi.org\/10.1016\/S0140-6736(10)60892-6","journal-title":"Lancet"},{"issue":"5","key":"4430_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40262-013-0130-1","volume":"53","author":"AH Salem","year":"2014","unstructured":"Salem AH, Giranda VL, Mostafa NM (2014) Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet 53(5):479\u2013488. https:\/\/doi.org\/10.1007\/s40262-013-0130-1","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"4430_CR49","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","volume":"18","author":"S Kummar","year":"2012","unstructured":"Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH (2012) A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 18(6):1726\u20131734. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2821","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4430_CR50","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","volume":"23","author":"I Gojo","year":"2017","unstructured":"Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE (2017) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res 23(3):697\u2013706. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0984","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4430_CR51","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-16-3068","volume":"23","author":"JD Soumerai","year":"2017","unstructured":"Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF (2017) The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma. Clin Cancer Res 23(15):4119\u20134126. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3068","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4430_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00280-017-3409-3","volume":"80","author":"R Stoller","year":"2017","unstructured":"Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH (2017) Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol 80(3):631\u2013643. https:\/\/doi.org\/10.1007\/s00280-017-3409-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4430_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00280-021-04350-x","volume":"89","author":"AR Tan","year":"2022","unstructured":"Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM (2022) A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemother Pharmacol 89(1):49\u201358. https:\/\/doi.org\/10.1007\/s00280-021-04350-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4430_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00280-020-04030-2","volume":"85","author":"B Pothuri","year":"2020","unstructured":"Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F (2020) Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer Chemother Pharmacol 85(4):741\u2013751. https:\/\/doi.org\/10.1007\/s00280-020-04030-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4430_CR55","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/A:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST (2000) Confidence interval criteria for assessment of dose proportionality. Pharm Res 17(10):1278\u20131283","journal-title":"Pharm Res"},{"issue":"1","key":"4430_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","volume":"8","author":"J Hummel","year":"2009","unstructured":"Hummel J, McKendrick S, Brindley C, French R (2009) Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8(1):38\u201349. https:\/\/doi.org\/10.1002\/pst.326","journal-title":"Pharm Stat"},{"key":"4430_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00092","author":"KV Ferry-Galow","year":"2018","unstructured":"Ferry-Galow KV, Datta V, Makhlouf HR, Wright J, Wood BJ, Levy E, Pisano ED, Tam AL, Lee SI, Mahmood U, Rubinstein LV, Doroshow JH, Chen AP (2018) What can be done to improve research biopsy quality in oncology clinical trials? J Oncol Practice\/Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JOP.18.00092","journal-title":"J Oncol Practice\/Am Soc Clin Oncol"},{"issue":"7716","key":"4430_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Alvarez-Quilon A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D (2018) The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560(7716):117\u2013121. https:\/\/doi.org\/10.1038\/s41586-018-0340-7","journal-title":"Nature"},{"key":"4430_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-4939-2963-4_19","volume":"1343","author":"C Delaney","year":"2015","unstructured":"Delaney C, Garg SK, Yung R (2015) Analysis of DNA methylation by pyrosequencing. Methods Mol Biol 1343:249\u2013264. https:\/\/doi.org\/10.1007\/978-1-4939-2963-4_19","journal-title":"Methods Mol Biol"},{"key":"4430_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-1-61779-055-3_12","volume":"724","author":"B Doyle","year":"2011","unstructured":"Doyle B, O\u2019Riain C, Appleton K (2011) Pyrosequencing of DNA extracted from formalin-fixed paraffin-embedded tissue. Methods Mol Biol 724:181\u2013190. https:\/\/doi.org\/10.1007\/978-1-61779-055-3_12","journal-title":"Methods Mol Biol"},{"issue":"7","key":"4430_CR61","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564\u2013569","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4430_CR62","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.trsl.2012.09.003","volume":"161","author":"W Duan","year":"2013","unstructured":"Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MA (2013) Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res 161(3):156\u2013164. https:\/\/doi.org\/10.1016\/j.trsl.2012.09.003","journal-title":"Transl Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04430-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T10:57:20Z","timestamp":1675335440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04430-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4430"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04430-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan Beumer received research support from AbbVie and has consulted as expert witness on behalf of Pfizer and Spectrum Pharmaceuticals. Shannon Puhalla has received research support from AbbVie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, AstraZeneca, Genentech, Medivation and has been a consultant for AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, and Nanostring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was registered under ClinicalTrials.gov Identifier: NCT01154426.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}